secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001214659-23-003896
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro Q3 net loss widens to $5.4M; cash $7.4M; clinical milestones on track
--------------------------------------------------------------------------------

- Net loss $5.4M ($0.06/share) vs $2.6M ($0.03/share) a year ago; R&D spend rose to $2.9M.
- Cash $7.4M at Jan 31, 2023; expects $14.8M non-dilutive note receivable in Dec 2023.
- Phase IIA topline for AL001 (Alzheimer's) expected June 2023; Phase I/IIA for ALZN002 to start March 2023.
- Working capital $5.8M; net cash used in operations $6.7M in nine months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465923003896/0001214659-23-003896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465923003896/b3162308k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-23-003896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer